Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CHS-828 is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor (IC50 = <25 nM).1 It selectively inhibits Nampt over nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 (NMN/NaMN adenylyltransferase 1) at 10 µM. CHS-828 (100 nM) reduces NAD+ levels in, and is cytotoxic to, HeLa cervical cancer cells. It decreases ATP levels in C666-1 nasopharyngeal and FaDu head and neck squamous cell carcinoma (HNSCC) cells in a time-dependent manner when used at concentrations of 10 and 20 nM, respectively.2 CHS-828 (100 and 250 mg/kg per week) reduces tumor growth in MCF-7 breast cancer and NYH small cell lung cancer mouse xenograft models.3
WARNING This product is not for human or veterinary use.
1. The small molecule GMX1778 is a potent inhibitor of NAD+ biosythesis: Strategy for enhanced therapy in nicotinic acid phophoribosyltransferase 1-
2. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin. Cancer Res. 16(3), 898-911 (2010).
3. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59(22), 5751-5757 (1999).